FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Ophthalmology Drugs in Phase IV Development in ISRAEL

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sodium Hyaluronate

            Therapeutic Area: Ophthalmology

            Highest Development Status: Phase IV Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bonus BioGroup

            Deal Size: $7.4 million Upfront Cash: Undisclosed

            Deal Type: Agreement January 16, 2020

            Details:

            This agreement will advance Wize Pharma's ongoing clinical program for LO2A, currently in a Phase IV study for the treatment of dry eye syndrome in patients with Sjogren's.